The relevance of TP53 for CLL diagnostics

Mark A. Catherwood, David Gonzalez de Castro, David Donaldson, Ruth Clifford, Ken I. Mills, Patrick D. Thornton

Research output: Contribution to journalReview article

Abstract

TP53 disruption in Chronic Lymphocytic Leukaemia ha long been known to hold vital prognostic information as well as dictate the appropriate course of treatment to be followed for patients. TP53 status is commonly assessed by FISH for del(17p) and Sanger sequencing for TP53 mutational analysis. At present, current screening methods for these mutations could miss diagnostically relevant mutations potentially leading to inappropriate treatment decisions. In addition low levels of mutations that are proving to be clinically relevant may not be detected with current techniques. This review looks at the structure, function and regulation of the TP53 protein, the mutations found in cancer and CLL, the relevance of TP53 disruption in CLL and the current screening methods for TP53 mutations including Next-generation sequencing.
LanguageEnglish
Pages343-346
Number of pages4
JournalJournal of Clinical Pathology
Volume72
Early online date02 Feb 2019
DOIs
Publication statusPublished - 16 Apr 2019

Fingerprint

Mutation
Tumor Suppressor Protein p53
B-Cell Chronic Lymphocytic Leukemia
Therapeutics
Neoplasms

Cite this

Catherwood, Mark A. ; Gonzalez de Castro, David ; Donaldson, David ; Clifford, Ruth ; Mills, Ken I. ; Thornton, Patrick D. / The relevance of TP53 for CLL diagnostics. In: Journal of Clinical Pathology. 2019 ; Vol. 72. pp. 343-346.
@article{9e7be8fd92d34c2995c3d171f9366187,
title = "The relevance of TP53 for CLL diagnostics",
abstract = "TP53 disruption in Chronic Lymphocytic Leukaemia ha long been known to hold vital prognostic information as well as dictate the appropriate course of treatment to be followed for patients. TP53 status is commonly assessed by FISH for del(17p) and Sanger sequencing for TP53 mutational analysis. At present, current screening methods for these mutations could miss diagnostically relevant mutations potentially leading to inappropriate treatment decisions. In addition low levels of mutations that are proving to be clinically relevant may not be detected with current techniques. This review looks at the structure, function and regulation of the TP53 protein, the mutations found in cancer and CLL, the relevance of TP53 disruption in CLL and the current screening methods for TP53 mutations including Next-generation sequencing.",
author = "Catherwood, {Mark A.} and {Gonzalez de Castro}, David and David Donaldson and Ruth Clifford and Mills, {Ken I.} and Thornton, {Patrick D.}",
year = "2019",
month = "4",
day = "16",
doi = "10.1136/jclinpath-2018-205622",
language = "English",
volume = "72",
pages = "343--346",
journal = "Journal of Clinical Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",

}

The relevance of TP53 for CLL diagnostics. / Catherwood, Mark A.; Gonzalez de Castro, David; Donaldson, David ; Clifford, Ruth; Mills, Ken I.; Thornton, Patrick D.

In: Journal of Clinical Pathology, Vol. 72, 16.04.2019, p. 343-346.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The relevance of TP53 for CLL diagnostics

AU - Catherwood, Mark A.

AU - Gonzalez de Castro, David

AU - Donaldson, David

AU - Clifford, Ruth

AU - Mills, Ken I.

AU - Thornton, Patrick D.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - TP53 disruption in Chronic Lymphocytic Leukaemia ha long been known to hold vital prognostic information as well as dictate the appropriate course of treatment to be followed for patients. TP53 status is commonly assessed by FISH for del(17p) and Sanger sequencing for TP53 mutational analysis. At present, current screening methods for these mutations could miss diagnostically relevant mutations potentially leading to inappropriate treatment decisions. In addition low levels of mutations that are proving to be clinically relevant may not be detected with current techniques. This review looks at the structure, function and regulation of the TP53 protein, the mutations found in cancer and CLL, the relevance of TP53 disruption in CLL and the current screening methods for TP53 mutations including Next-generation sequencing.

AB - TP53 disruption in Chronic Lymphocytic Leukaemia ha long been known to hold vital prognostic information as well as dictate the appropriate course of treatment to be followed for patients. TP53 status is commonly assessed by FISH for del(17p) and Sanger sequencing for TP53 mutational analysis. At present, current screening methods for these mutations could miss diagnostically relevant mutations potentially leading to inappropriate treatment decisions. In addition low levels of mutations that are proving to be clinically relevant may not be detected with current techniques. This review looks at the structure, function and regulation of the TP53 protein, the mutations found in cancer and CLL, the relevance of TP53 disruption in CLL and the current screening methods for TP53 mutations including Next-generation sequencing.

U2 - 10.1136/jclinpath-2018-205622

DO - 10.1136/jclinpath-2018-205622

M3 - Review article

VL - 72

SP - 343

EP - 346

JO - Journal of Clinical Pathology

T2 - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

ER -